Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings results on Thursday, May, 4th. The company reported $2.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.42. The company earned $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The firm's revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.57 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

26 brokers have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $345.00 to $598.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $472.96 in the next twelve months. View Analyst Ratings for Regeneron Pharmaceuticals.

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and Regeneron is evaluating the drug for additional indications like asthma. The approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU will further diversify the company’s portfolio. On the other hand, although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is expected to have blockbuster potential. Shares of the company have also outperformed the industry in the year so far." (7/4/2017)
• 2. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
• 3. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)
• 4. Robert W. Baird analysts commented, "We surveyed 30 dermatologists treating ~134 moderate-to-severe AD patients each on their expectations around the launches for Pfizer's Eucrisa and Regeneron/Sanofi's Dupixent, set for approval tomorrow. Docs highlighted the significant need for new mechanisms and therapeutic alternatives. Importantly, physician sentiment points to a market for Dupixent of about 300,000-350,000 patients, in line with management's expectations. We wouldn't be surprised to see an exceptionally strong launch here, but we continue to point out that consensus expectations are already building that in." (3/28/2017)

Some companies that are related to Regeneron Pharmaceuticals include Celgene Corporation (CELG), Gilead Sciences (GILD), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO) and Prothena Corporation PLC (PRTA).

Regeneron Pharmaceuticals' management team includes the folowing people:

• P. Roy Vagelos M.D., Chairman of the Board
• Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
• Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
• Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
• Neil Stahl Ph.D., Executive Vice President - Research and Development
• Robert J. Terifay, Executive Vice President - Commercial
• Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
• Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
• Peter Powchik M.D., Senior Vice President - Clinical Development
• George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Regeneron Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Manning & Napier Advisors LLC (0.28%), Rockefeller Financial Services Inc. (0.12%), Chevy Chase Trust Holdings Inc. (0.09%), National Pension Service (0.06%), Bank of Montreal Can (0.04%) and Aperio Group LLC (0.03%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Peter Powchik, Plew Daniel P Van, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Rockefeller Financial Services Inc., APG Asset Management N.V., Bank of Montreal Can, Oakbrook Investments LLC, Exxonmobil Investment Management Inc. TX, Cypress Asset Management Inc. TX and Leavell Investment Management Inc.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Chevy Chase Trust Holdings Inc., Barometer Capital Management Inc., Mn Services Vermogensbeheer B.V., Aperio Group LLC, National Pension Service, Deane Retirement Strategies Inc., Sheets Smith Wealth Management and Meeder Asset Management Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $521.22.